Imaging features to predict clinical endpoints in chronic liver disease - a scoping review

Study data entry proforma

• • •

N.B.: Please check that the study meets the inclusion criteria first!

If not, explain why in the final question, submit and email m.chouhan@ucl.ac.uk with the study details.

1. Researcher initials:

Enter your answer

2. DOI:

Enter your answer

3. Author:

(e.g. Smith et al.)

Enter your answer

4. Year:

(Format: YYYY)

The value must be a number

5. Country:

Enter your answer

6. Imaging modalities used:

- [ ] US
- [ ] CT
- [ ] MRI

7. Study type

(n.b. prognostic studies only - if not prognostic, enter "not prognostic" in question 35 and submit blank form)

- [ ] Retrospective
- [ ] Prospective
- [ ] Other

8. Recruitment setting:

- [ ] Outpatient
- [ ] Inpatient
- [ ] Patient registry

☐ Other

9. Prognostic study phase:

☐ Phase Ia

☐ Phase Ib

☐ Phase IIa

☐ Phase IIb

☐ Phase III

☐ Other

10. Overall sample size:

The value must be a number

11. Non-liver disease sub-cohort size:

(i.e. healthy volunteers, non-liver disease patients, if no non-liver disease sub-cohort, just type "0")

The value must be a number

12. Non-liver disease sub-cohort:

☐ No non-liver disease sub-cohort studied

☐ Healthy volunteers

☐ Non-liver disease patients

☐ Age-matched controls

☐ Other

13. Liver disease sub-cohort size:

(pooled across all liver disease aetiologies, if multiple)

The value must be a number

14. Liver disease aetiologies studied:

☐ Viral hepatitis

☐ Alcoholic liver disease

☐ NASH

☐ NAFLD

☐ PSC

☐ PBC

☐ Autoimmune hepatitis

☐ Unspecified

☐ Other

15. Development sample size:

(for phase Ia studies only - if not applicable, enter '0')

The value must be a number

16. Internal validation/test sample size:

(for phase Ib studies and above only - if not applicable, enter '0')

The value must be a number

17. Interval validation/test sampling method:

(if no interval validation/test sample, just select 'N/A')

- ◯ Random development/validation dataset split
- ◯ Re-sampling of the same data (e.g. bootstrap or cross-validation methods)
- ◯ N/A
- ◯ Other

18. External validation/test sample size:

(for phase Ib studies and above only - if not applicable, enter '0')

The value must be a number

19. External validation/test sample cohort notes:

(3 details - disease aetiology - site (e.g. single, multiple) - separation from development cohort (e.g. random, temporal, geographic); if no external validation/test sample, just enter 'N/A'),

For example:
NAFLD - single site - geographic separation

Enter your answer

20. Clinical endpoints:

(include primary and secondary clinical endpoints)

- ☐ Mortality/Survival
- ☐ Acute decompensation

- [ ] Hepatic encephalopathy
- [ ] Jaundice
- [ ] Intractable ascites
- [ ] Variceal bleed
- [ ] Development of HCC
- [ ] Deterioration in decompensation
- [ ] Transplant/Transplant free survival
- [ ] Other

21. Clinical endpoint sample size:

(please enter sample size for each endpoint, each on a new line, in the box below)

For example:
Mortality, n=25
Acute decompensation, n=30

Enter your answer

22. Follow-up interval (for the development cohort):

(average/fixed, months)

The value must be a number

23. Follow-up interval data-type (for the development cohort):

(referring to question 22)

- ○ Mean
- ○ Median
- ○ Fixed

- ◯ Other

24. Average follow-up interval (+/- limit or range, for the development cohort):
(enter '0' if follow-up interval fixed)

Enter your answer

25. Average follow-up interval +/- limit data-type (for the development cohort):
(referring to question 24)

- ◯ Standard Deviation
- ◯ Standard Error
- ◯ Inter-quartile range
- ◯ Range
- ◯ Confidence Interval
- ◯ N/A (fixed)
- ◯ Other

26. Follow-up interval (for the test/validation cohort):
(average/fixed, months)

The value must be a number

27. Follow-up interval data-type (for the test/validation cohort):
(referring to question 26)

- ◯ Mean
- ◯ Median

- ◯ Fixed
- ◯ Other

28. Average follow-up interval +/- limit (for the test/validation cohort):

(enter '0' if follow-up interval fixed)

The value must be a number

29. Average follow-up interval +/- limit data-type (for the test/validation cohort):

(referring to question 28)

- ◯ Standard Deviation
- ◯ Standard Error
- ◯ Inter-quartile range
- ◯ Range
- ◯ Confidence Interval
- ◯ N/A (fixed)
- ◯ Other

30. Number of scanners used:

(if not stated, record 'not given')

Enter your answer

31. Number of participating institutions/hospitals/imaging centres:

The value must be a number

32. Anatomical features evaluated 1:

(thematic grouping)

- [ ] Splenic size (single dimension/volumetry)
- [ ] Liver size (single dimension/volumetry)
- [ ] Porto-systemic shunts (single dimension/volumetry)
- [ ] Portal vein (diameter)
- [ ] Splenic vein (diameter)
- [ ] Liver contour (qualitative/quantitative)
- [ ] Liver radiomics/textural features
- [ ] Spleen radiomics/textural features
- [ ] Ascites (presence/volumetry)
- [ ] Fat (visceral/subcutaneous adiposity)
- [ ] Muscle (sarcopaenia)
- [ ] Other

33. Anatomical features evaluated 2:

(specific variables measured from themes given previously)

For example:
splenic size - craniocaudal length (mm)
liver size - mid-clavicular line length (mm)
porto-systemic shunt - azygous vein diameter (mm)
porto-systemic shunt - presence of recanalised umbilical vein

Enter your answer

34. Anatomical features linked with clinical endpoints 1:

(thematic grouping)

- [ ] Splenic size (single dimension/volumetry)
- [ ] Liver size (single dimension/volumetry)
- [ ] Porto-systemic shunts (single dimension/volumetry)
- [ ] Portal vein (diameter)
- [ ] Splenic vein (diameter)
- [ ] Liver contour (qualitative/quantitative)
- [ ] Liver radiomics/textural features
- [ ] Spleen radiomics/textural features
- [ ] Ascites (presence/volumetry)
- [ ] Fat (visceral/subcutaneous adiposity)
- [ ] Muscle (sarcopaenia)
- [ ] Other

35. Anatomical features linked with clinical endpoints 2:

(list theme, then feature and hifen to separate endpoint associated with, new feature/linked endpoint on each line)

For example:
splenic size - spleen volume - acute decompensation
sarcopaenia - psoas muscle area at L3 - hepatic encephalopathy
visceral fat - L3 visceral fat area % - development of HCC

Enter your answer

36. Statistical analysis method:

- [ ] Cox regression
- [ ] Regression
- [ ] t-tests

- [ ] Chi-squared tests
- [ ] Wilcoxon rank sum
- [ ] ANOVA
- [ ] Correlation
- [ ] ROC analysis
- [ ] Other

37. Prognostic model developed:

- ○ Single variable
- ○ > 1 variable/composite model
- ○ Other

38. Prognostic model presentation

- [ ] Full regression formula (coefficients + intercept/baseline hazard)
- [ ] Partial regression formula (hazard/odds ratio, no intercept/baseline hazard)
- [ ] Sum score
- [ ] Nomogram
- [ ] Online tool
- [ ] Not given
- [ ] Other

39. Prognostic model usability

- [ ] Prognostic score/risk group assigned
- [ ] Time-to-endpoint presented for risk group/score

- [ ] Data driven threshold/cut-off value
- [ ] Instructions for clinical use given
- [ ] Not given
- [ ] Other

40. Additional notes (including why a study does not meet inclusion criteria):

(please print as a PDF to save a copy of your completed proforma before hitting the 'submit' button)

Enter your answer

Submit

Never give out your password. Report abuse

This content is created by the owner of the form. The data you submit will be sent to the form owner. Microsoft is not responsible for the privacy or security practices of its customers, including those of this form owner. Never